{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:22:55Z","timestamp":1770484975403,"version":"3.49.0"},"reference-count":71,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Compar. Effect. Res."],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold>Generic atypical antipsychotic drugs should be a focus of attention given their expenditure. However, there is a recognized need to tailor treatments. There were no specific measures in Belgium to enhance the prescribing of oral risperidone following generics in January 2008. Prescribing restrictions have remained for long-acting risperidone injections throughout.<jats:bold>Objective:<\/jats:bold>Assess changes in risperidone utilization before and after oral generics were reimbursed, as well as the utilization and expenditure of the various risperidone preparations.<jats:bold>Method:<\/jats:bold>Principally a retrospective observational study and interrupted time series design.<jats:bold>Results:<\/jats:bold>As expected, no increased utilization of oral risperidone after generics. Both originator and generic oral risperidone prescribed, with the originator reducing its price. Generic risperidone was 59% below prepatent loss prices by September 2012.<jats:bold>Conclusion:<\/jats:bold>Authorities cannot rely on a \u2018spill over\u2019 of learning from other disease areas to affect changes in physician prescribing habits. Specific measures are needed to encourage generic risperidone where appropriate. However, their influence will be limited by the complexity of the disease area.<\/jats:p>","DOI":"10.2217\/cer.13.75","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T17:52:41Z","timestamp":1383587561000},"page":"551-561","source":"Crossref","is-referenced-by-count":14,"title":["Generic atypical antipsychotic drugs in Belgium: their influence and implications"],"prefix":"10.57264","volume":"2","author":[{"given":"Brian","family":"Godman","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden."},{"name":"Strathclyde Institute of Pharmacy &amp; Biomedical Sciences, University of Strathclyde, Glasgow, UK"},{"name":"National Institute of Science &amp; Technology on Innovation on Neglected Diseases, Centre for Technological Development in Health, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristien","family":"De Bruyn","sequence":"additional","affiliation":[{"name":"Statistics Department, Association of Belgian Pharmacists, Archimedesstraat 11, B-1000 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamilette","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Development, Public Healthcare Services Committee Administration, Stockholm County Council, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[{"name":"Department of Medical &amp; Surgical Sciences, Alma Mater Studiorum \u2013 University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Bennie","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy &amp; Biomedical Sciences, University of Strathclyde, Glasgow, UK"},{"name":"Public Health &amp; Intelligence Strategic Business Unit, NHS National Services Scotland, Edinburgh, EH12 9EB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Research and Training in Mental Health &amp; Service Evaluation, Department of Public Health &amp; Community Medicine, Section of Psychiatry, University of Verona, Policlinico G.B. Rossi, Piazzale L.A. Scuro 10, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[{"name":"KU Leuven, Department of Pharmaceutical &amp; Pharmacological Sciences, KU Leuven, Herestraat 49, O &amp; N 2 Bus 521, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_3_3_1_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03256162","volume":"8","author":"Sermet","year":"2010","unstructured":"Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7\u201324 (2010).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"e_1_3_3_3_2_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/14737167.9.1.65","volume":"9","author":"Godman","year":"2009","unstructured":"Godman B, Wettermark B, Hoffman M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65\u201383 (2009).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_3_3_3_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(08)61762-6","volume":"373","author":"Cameron","year":"2009","unstructured":"Cameron A, Ewan M, Ross-Degnan D et al. Medicine prices, availability and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373, 240\u2013249 (2009).","journal-title":"Lancet"},{"key":"e_1_3_3_3_4_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5639\/gabij.2012.0102.017","volume":"1","author":"Godman","year":"2012","unstructured":"Godman B, Abuelkhair M, Vitry A et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBI 1(2), 69\u201383 (2012).","journal-title":"GaBI"},{"key":"e_1_3_3_3_5_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/erp.11.42","volume":"11","author":"Voncina","year":"2011","unstructured":"Voncina L, Strizrep T, Godman B et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469\u2013479 (2011).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_3_3_6_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/erp.10.72","volume":"10","author":"Godman","year":"2010","unstructured":"Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707\u2013722 (2010).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_3_3_7_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1759-8893.2011.00061.x","volume":"2","author":"Dylst","year":"2011","unstructured":"Dylst P, Vulto A, Simoens S et al. Where a cheap medicine is not the same as a generic medicine: the Belgian case. JPHSR 2, 185\u2013199 (2011).","journal-title":"JPHSR"},{"key":"e_1_3_3_3_8_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5639\/gabij.2012.0101.004","volume":"1","author":"Simoens","year":"2012","unstructured":"Simoens S. A review of generic medicine pricing in Europe. GaBI 1, 8\u201312 (2012).","journal-title":"GaBI"},{"key":"e_1_3_3_3_9_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10198-011-0367-2","volume":"13","author":"Vrijens","year":"2012","unstructured":"Vrijens F, Van de Voorde C, Farfan-Portet MI, Vander Stichele R. Patient socieoeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur. J. Health Econ. 13(3), 315\u2013325 (2012).","journal-title":"Eur. J. Health Econ."},{"key":"e_1_3_3_3_10_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/jphs.12024","volume":"4","author":"Simoens","year":"2013","unstructured":"Simoens S, Godman B, De Bruyn K, Miranda J, Malmstr\u00f6m RE. Measures to enhance ARB prescribing efficiency in Belgium following generic losartan: impact and implications for the future. JPHSR 4(3), 173\u2013181 (2013).","journal-title":"JPHSR"},{"key":"e_1_3_3_3_11_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/erp.12.88","volume":"13","author":"Fraeyman","year":"2013","unstructured":"Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to improve prescribing efficiency for proton pump inhibitors (PPIs) and statins in Belgium. Expert Rev. Pharmacoecon. Outcomes Res. 13, 141\u2013151 (2013).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_3_3_12_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11318840-000000000-00000","volume":"9","author":"Wladysiuk","year":"2011","unstructured":"Wladysiuk M, Araszkiewicz A, Godman B et al. Patient co-payments do influence atypical antipsychotic choice in Poland; implications once generic atypcials are available. Appl. Health Econ. Health Policy 9, 101\u2013110 (2011).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"e_1_3_3_3_13_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00127-005-0852-y","volume":"40","author":"Andretta","year":"2005","unstructured":"Andretta M, Ciuna A, Corbari L et al. Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc. Psychiatry Psychiatr. Epidemiol. 40, 72\u201377 (2005).","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"e_1_3_3_3_14_2","first-page":"e109","volume":"18","author":"Leslie","year":"2012","unstructured":"Leslie D, Rosenheck R. Off-label use of antipsychotic medications in Medicaid. Am. J. Manag. Care 18(3), e109\u2013e117 (2012).","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_3_3_15_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2191-1991-2-9","volume":"2","author":"Zeidler","year":"2012","unstructured":"Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ. Rev. 2(1), 9 (2012).","journal-title":"Health Econ. Rev."},{"key":"e_1_3_3_3_16_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2009.03.027","volume":"111","author":"Salize","year":"2009","unstructured":"Salize H, McCabe, Bullenkamp J et al. Cost of treatment of schizophrenia in six European countries. Schizophr. Res. 111(1\u20133), 70\u201377 (2009).","journal-title":"Schizophr. Res."},{"key":"e_1_3_3_3_17_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.sapharm.2009.07.001","volume":"9","author":"Wang","year":"2013","unstructured":"Wang C-C, Farley J. Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel Survey. Res. Social Adm. Pharm. 9, 263\u2013275 (2013).","journal-title":"Res. Social Adm. Pharm."},{"key":"e_1_3_3_3_18_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.sapharm.2011.04.003","volume":"8","author":"Wheeler","year":"2012","unstructured":"Wheeler A, Crump K, Lee M, Li L, Patel P, Yang R. Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health. Res. Social Adm. Pharm. 8, 179\u2013192 (2012).","journal-title":"Res. Social Adm. Pharm."},{"key":"e_1_3_3_3_19_2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","volume":"361","author":"Leucht","year":"2003","unstructured":"Leucht S, Wahlbeck K, Hamann J et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361(9369), 1581\u20131589 (2003).","journal-title":"Lancet"},{"key":"e_1_3_3_3_20_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(08)61765-1","volume":"373","author":"Tyrer","year":"2009","unstructured":"Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 373(9657), 4\u20135 (2009).","journal-title":"Lancet"},{"key":"e_1_3_3_3_21_2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","volume":"172","author":"Gardner","year":"2005","unstructured":"Gardner D, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 172(13), 1703\u20131711 (2005).","journal-title":"CMAJ"},{"key":"e_1_3_3_3_22_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2009.06.008","volume":"113","author":"Edlinger","year":"2009","unstructured":"Edlinger M, Hofer A, Rettenbacher M et al. Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophr. Res. 113, 246\u2013251 (2009).","journal-title":"Schizophr. Res."},{"key":"e_1_3_3_3_23_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200528010-00003","volume":"28","author":"Titier","year":"2005","unstructured":"Titier K, Girodet PO, Verdoux H et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 28(1), 35\u201351 (2005).","journal-title":"Drug Saf."},{"key":"e_1_3_3_3_24_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","volume":"21","author":"Haddad","year":"2007","unstructured":"Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21(11), 911\u2013936 (2007).","journal-title":"CNS Drugs"},{"key":"e_1_3_3_3_25_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 360(3), 225\u2013235 (2009).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_3_26_2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/11318880-000000000-00000","volume":"26","author":"Vieweg","year":"2009","unstructured":"Vieweg WV, Wood MA, Fernandez A. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26(12), 997\u20131012 (2009).","journal-title":"Drugs Aging"},{"key":"e_1_3_3_3_27_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"Poluzzi","year":"2009","unstructured":"Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol. Drug Saf. 18(6), 512\u2013518 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"e_1_3_3_3_28_2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11096-011-9541-y","volume":"33","author":"Meyer-Massetti","year":"2011","unstructured":"Meyer-Massetti C, Vaerini S, R\u00e4tz Bravo AE et al. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int. J. Clin. Pharm. 33(5), 806\u2013814 (2011).","journal-title":"Int. J. Clin. Pharm."},{"key":"e_1_3_3_3_29_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40264-013-0032-z","volume":"36","author":"Poluzzi","year":"2013","unstructured":"Poluzzi E, Raschi E, Koci A et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System Database. Drug Saf. 36(6), 467\u2013479 (2013).","journal-title":"Drug Saf."},{"key":"e_1_3_3_3_30_2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"Tiihonen","year":"2009","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck W et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690), 620\u2013627 (2009).","journal-title":"Lancet"},{"key":"e_1_3_3_3_31_2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209\u20131223 (2005).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_3_32_2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1176\/appi.ajp.2011.11010039","volume":"168","author":"Lieberman","year":"2011","unstructured":"Lieberman JA, Stroup T. Commentary \u2013 The NIM H-CAT IE Schizophrenia Study: What did we learn? Am. J. Psychiatry 168, 770\u2013775 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"e_1_3_3_3_33_2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4088\/JCP.10m06497","volume":"73","author":"Berkowitz","year":"2012","unstructured":"Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J. Clin. Psychiatry 73(4), 498\u2013503 (2012).","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_3_3_3_34_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/j.1440-1614.2005.01509.x","volume":"39","author":"Magnus","year":"2005","unstructured":"Magnus A, Carr V, Mihalopoulos C et al. Assessing cost\u2013effectiveness of drug interventions for schizophrenia. Aust. NZ J. Psychiatry 39, 44\u201354 (2005).","journal-title":"Aust. NZ J. Psychiatry"},{"key":"e_1_3_3_3_35_2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1377\/hlthaff.28.5.w770","volume":"28","author":"Crystal","year":"2009","unstructured":"Crystal S, Olfson M, Huang C et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff. 28(5), 770\u2013781 (2009).","journal-title":"Health Aff."},{"key":"e_1_3_3_3_36_2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 168(6), 603\u2013609 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"e_1_3_3_3_37_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","volume":"20","author":"Alexander","year":"2011","unstructured":"Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995\u20132008. Pharmacoepidemiol. Drug Saf. 20, 177\u2013184 (2011).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"e_1_3_3_3_38_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/14737167.2013.820956","volume":"13","author":"Godman","year":"2013","unstructured":"Godman B, Bishop I, Finlayson AE, Campbell S, Kwon H-Y, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 13(4), 469\u2013482 (2013).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_3_3_39_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/ijcp.12130","volume":"67","author":"Godman","year":"2013","unstructured":"Godman B, Wettermark B, Miranda J et al. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int. J. Clin. Pract. 67(9), 853\u2013862 (2013).","journal-title":"Int. J. Clin. Pract."},{"key":"e_1_3_3_3_40_2","first-page":"30","volume":"342","author":"Moon","year":"2011","unstructured":"Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ 342, 30\u201332 (2011).","journal-title":"BMJ"},{"key":"e_1_3_3_3_41_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1742-1241.2007.01690.x","volume":"62","author":"Usher-Smith","year":"2008","unstructured":"Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480\u2013484 (2008).","journal-title":"Int. J. Clin. Pract."},{"key":"e_1_3_3_3_42_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/ijcp.12100","volume":"67","author":"Bennie","year":"2013","unstructured":"Bennie M, Bishop I, Godman B et al. Are specific initiatives required to enhance the prescribing of generic atypical antipsychotics in Scotland; international implications? Int. J. Clin. Pract. 67(2), 170\u2013180 (2013).","journal-title":"Int. J. Clin. Pract."},{"key":"e_1_3_3_3_43_2","first-page":"198","volume":"3","author":"Godman","year":"2012","unstructured":"Godman B, Buscics A, Burkhardt T et al. Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future. Front. Pharmacol. 3, 198 (2012).","journal-title":"Front. Pharmacol."},{"key":"e_1_3_3_3_44_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1586\/erp.10.87","volume":"11","author":"Godman","year":"2011","unstructured":"Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11, 121\u2013129 (2011).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_3_3_45_2","first-page":"CD006633","volume":"11","author":"Asenjo Lobos","year":"2010","unstructured":"Asenjo Lobos C, Komossa K, Rummel-Kluge C et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 11, CD006633 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_3_46_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S1461145710001380","volume":"14","author":"Leucht","year":"2011","unstructured":"Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int. J. Neuropsychopharmacol. 14(2), 269\u2013284 (2011).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"e_1_3_3_3_47_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/157488611797579230","volume":"6","author":"Raja","year":"2011","unstructured":"Raja M. Clozapine safety, 35 years later. Curr. Drug Saf. 6(3), 164\u2013184 (2011).","journal-title":"Curr. Drug Saf."},{"key":"e_1_3_3_3_48_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11096-010-9366-0","volume":"32","author":"Vlahovic-Palcevski","year":"2010","unstructured":"Vlahovic-Palcevski V, Gantumur M, Radosevic N et al. Coping with changes in Defined Daily Dose in longitudinal drug consumption databases. Pharm. World Sci. 32, 125\u2013129 (2010).","journal-title":"Pharm. World Sci."},{"key":"e_1_3_3_3_49_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s002280000200","volume":"56","author":"R\u00f8nning","year":"2000","unstructured":"R\u00f8nning M, Blix HS, Harb\u00f8 BT, Str\u00f8m H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose \u2013 are drug utilisation data comparable? Eur. J. Clin. Pharmacol. 56, 723\u2013727 (2000).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_3_3_50_2","unstructured":"McDowall D McCleary R Meidinger EE Hay RA. Chapter 2: the stochastic component. In: Sage University Papers Series on Quantitative Applications in the Social Sciences 07\u2013021. Weber R (Ed.). Sage Publications Inc. CA USA 15\u201363 (1980)."},{"key":"e_1_3_3_3_51_2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/jama.1993.03510160055029","volume":"270","author":"Ross-Degnan","year":"1993","unstructured":"Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH. Examining product risk in context. Market withdrawal of zomepirac as a case study. JAMA 270, 1937\u20131942 (1993).","journal-title":"JAMA"},{"key":"e_1_3_3_3_52_2","first-page":"409","volume":"37","author":"Durbin","year":"1951","unstructured":"Durbin J, Watson GS. Testing for serial correlation in least square regression. Biometrika 37, 409\u2013428 (1951).","journal-title":"Biometrika"},{"key":"e_1_3_3_3_53_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/bmj.309.6956.727","volume":"309","author":"Brennan","year":"1994","unstructured":"Brennan P, Croft P. Interpreting the results of observational research: chance is not such a fine thing. BMJ 309, 727\u2013730 (1994).","journal-title":"BMJ"},{"key":"e_1_3_3_3_54_2","first-page":"55","volume":"21","author":"Godman","year":"2012","unstructured":"Godman B, Bennett K, Bennie M et al. Are health authorities and health insurance companies taking full advantage of the availability of generic risperidone; implications for the future? Pharmacoepidemiol. Drug Saf. 21(Suppl. 3), 55\u201356 (2012).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"e_1_3_3_3_55_2","first-page":"CD006654","volume":"3","author":"Komossa","year":"2010","unstructured":"Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Sys. Rev. 3, CD006654 (2010).","journal-title":"Cochrane Database Sys. Rev."},{"key":"e_1_3_3_3_56_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/schbul\/sbn019","volume":"35","author":"Parks","year":"2009","unstructured":"Parks J, Radke A, Parker G et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr. Bull. 35, 931\u2013936 (2009).","journal-title":"Schizophr. Bull."},{"key":"e_1_3_3_3_57_2","first-page":"160","volume":"67","author":"Fraeyman","year":"2012","unstructured":"Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer G, Beutels P. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin. Belg. 67(3), 160\u2013171 (2012).","journal-title":"Acta Clin. Belg."},{"key":"e_1_3_3_3_58_2","first-page":"7","volume":"21","author":"Bennie","year":"2013","unstructured":"Bennie M, Bishop I, Godman B et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Qual. Prim. Care 21, 7\u201315 (2013).","journal-title":"Qual. Prim. Care"},{"key":"e_1_3_3_3_59_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/erp.12.71","volume":"12","author":"Bucsics","year":"2012","unstructured":"Bucsics A, Godman B, Burkhardt T et al. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilisation patterns in Austria; implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 12, 809\u2013819 (2012).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_3_3_60_2","unstructured":"Martin A Godman B Miranda J et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications (Submitted to Journal of Comparative Effectiveness Research)."},{"key":"e_1_3_3_4_2_2","unstructured":"Organisation for Economic Cooperation and Development (OECD).Pharmaceutical expenditure in OECD Health at a Glance 2011: OECD Indicators. www.oecd-ilibrary.org\/social-issues-migration-health\/health-at-a-glance-2011\/pharmaceutical-expenditure_health_glance-2011-63-en (Accessed 6 June 2013)"},{"key":"e_1_3_3_4_3_2","unstructured":"WHO. International language for drug utilization research. www.whocc.no (Accessed 5 June 2013)"},{"key":"e_1_3_3_4_4_2","unstructured":"NICE. Schizophrenia \u2013 core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 82 (March 2009). www.nice.org.uk\/nicemedia\/live\/11786\/43610\/43610.pdf (Accessed 5 June 2013)"},{"key":"e_1_3_3_4_5_2","unstructured":"NICE implementation uptake report: atypical antipsychotic drugs for the treatment of schizophrenia. NICE Technology appraisals 43. www.nice.org.uk\/media\/410\/E9\/ImplUptakeReportAtypicalAntipsychotics.pdf (Accessed 5 June 2013)"},{"key":"e_1_3_3_4_6_2","unstructured":"RIZIV-INAMI Nota ARVG 2011\/88. www.riziv.be\/drug\/all\/drugs\/reglementation\/medicalproducts\/last\/pdf\/chapter4.pdf (Accessed 10 August 2013)"},{"key":"e_1_3_3_4_7_2","unstructured":"Law on various clauses \u2013 Pluriannual Estimates Act Omnibus Act Art. www.ejustice.just.fgov.be\/cgi_loi\/change_lg.pl?language=fr&la=F&cn=2012032901&table_name=loi (Accessed 10 June 2013)"},{"key":"e_1_3_3_4_8_2","unstructured":"Healthcare Department of Belgium\u2019s National Institute for Health and Disability Insurance \u2013 Pharmaceutical Policy Management Unit Healthcare Department. Global analytical report on the content of Pharmanet \u2013 singular pathway. www.riziv.be\/drug\/nl\/statistics-scientific-information\/pharmanet\/introduction\/pdf\/analyticalreport_eng.pdf (Accessed 3 August 2013)"},{"key":"e_1_3_3_4_9_2","unstructured":"WHO. Introduction to Drug Utilization Research. WHO International 108. Working Group for Drug Statistics Methodology WHO Collaborating Centre for Drug Statistics Methodology WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/Drug%20utilization%20research.pdf (Accessed 8 June 2013)"},{"key":"e_1_3_3_4_10_2","unstructured":"Fisk M Feeley J Voreacos D. J&J Said to Agree to $2.2 Billion Drug Marketing Accord. www.bloomberg.com\/news\/2012-06-11\/j-j-said-to-pay-2-2-billion-to-end-risperdal-sales-probe.html (Accessed 8 June 2013)"},{"key":"e_1_3_3_4_11_2","unstructured":"Department of Justice settlement agreement. www.justice.gov\/usao\/pae\/Pharma-Device\/astrazeneca_settlementagreement.pdf (Accessed 8 June 2013)"},{"key":"e_1_3_3_4_12_2","unstructured":"Jack A. AstraZeneca faces $520m Seroquel fine. www.ft.com\/cms\/s\/0\/319e31d4-5251-11df-8b09-00144feab49a.html#axzz26q1gMSgc (Accessed 8 June 2013)"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer.13.75","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T06:26:34Z","timestamp":1716099994000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer.13.75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.2217\/cer.13.75"],"URL":"https:\/\/doi.org\/10.2217\/cer.13.75","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}